Fig. 4
From: Modulation of SLFN11 induces changes in DNA Damage response in breast cancer
CRISPR-dCas9 modulation of SLFN11 impact sensitivity to DNA Damaging agents. A, B, E, F, I, J In BT-549, SLFN11 increase with UNISAM (gRNA N7) or decrease with KRAB (gRNA N7) leads to respectively significant increase and decreased sensitivity to Cisplatin treatment (N = 4, biological replicates) (A, B) Epirubicin treatment (E, F) (N = 4, biological replicates) and Olaparib (N = 4, biological replicates) (I, J) compared to respective scramble (SCR) controls. Only in Olapraib the decrease of SLFN11 with KRAB (gRNA N7) did not bring significant difference with SCR control at the indicated concentration. C, D, G, H, K, L In T47D, SLFN11 increase with UNISAM (gRNA N7) or decrease with KRAB (gRNA N7) leads to respectively significant increase and decreased sensitivity to Cisplatin treatment (N = 4, biological replicates) (C, D) Epirubicin treatment (G, H) (N = 3, biological replicates) and Olaparib (N = 4, biological replicates) compared to respective scramble (SCR) controls. K, L Only in Cisplatin the decrease of SLFN11 with KRAB (gRNA N7) did not bring significant difference with SCR control at the indicated concentration